Skip to main content

908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS

Written By Labx.com

BOSTON, MA — 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, showcased the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70th American Society for Mass Spectrometry (ASMS) Conference June 5–9 in Minneapolis. The presentations, which included one oral and eleven posters, highlighted technology to accelerate drug development workflows, and included collaborators such as Boehringer Ingelheim, Genentech, University of Washington, Fudan University, and Dana-Farber Cancer Institute.

Mass Spec for the Masses

908 Devices is democratizing mass spec with its handheld and desktop devices that are simple to operate, provide answers in minutes, and are used at the point of need, making mass spec more accessible to more scientists.

The company’s ZipChip® device leverages microfluidic-based Capillary Electrophoresis (CE) and electrospray ionization technology to minimize sample prep burden, perform high-resolution separations, and directly introduce samples into a Thermo Fisher Scientific, Bruker, or Sciex mass spectrometer.

The majority of the ASMS presentations by 908 Devices and its collaborators noted the use of ZipChip in either oligonucleotides, metabolomics, or proteomics applications—all areas of increasing importance in the development of new therapeutics. The ZipChip Oligos assay kit provides a fast and simple means to obtain high-resolution separation and mass spec data from a wide range of oligonucleotides, with minimal sample prep and without the need of harsh ion pairing reagents.

In the area of proteomics, the company highlighted updates to its microfluidic prototype chip developments that couple solid phase extraction to accommodate larger sample volumes as well as chip increases in speed and sensitivity. Scientists from the Dana-Farber Cancer Institute presented their research utilizing the prototype chips for “warp-speed profiling” of deubiquitinase small molecule inhibitors.

In addition, 908 Devices presented two posters on quantitation of amino acids in cell culture media using its REBEL™ desktop device, a first-of-its-kind fresh and spent media analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line.

Exhibit and Presentations at ASMS

Here is a list of ASMS presentations by 908 Devices and collaborators:

Oral Presentation

Pushing theBoundaries of Speed and Sensitivity in Proteomics: Coupling SPE-enabledMicrofluidic Capillary Electrophoresis with Ultrafast Tandem Mass Spectrometry
Collaboration: 908 Devices, Thermo Fisher Scientific, University of Washington

Poster Presentations

A BroadApplication of Migration Time Indexing and Metabolite Libraries to EvaluateQuantitative Coverage in Microchip CE-MS Metabolomics
908 Devices

Dynamic Range Optimization for Amino Acid Quantitation with an Integrated CE-MS Analyzer
908 Devices

GlycosylationProfiling of Cetuximab Subunits with CZE-MS
Collaboration: 908 Devices, Bruker

CapillaryElectrophoresis Mass Spectrometry (CEMS) of Oligonucleotides using a 908Devices ZipChip
Collaboration: 908 Devices, Boehringer Ingelheim

Microchip CE-MS Analysis of Sialylated N-glycan Linkage Isomers
Collaboration: 908 Devices, Fudan University

A Sensitive and High-Throughput Assay for Analyzing Peptide Exchanged MHCI by High Resolution Native CZE-MS
Collaboration: 908 Devices, Genentech

Combining µSPE Chip-based CE with PRM-LIVE and Dynamic Targeting Scheduling for Warp-speed Selectivity Profiling of Deubiquitinase Small Molecule Inhibitors
Collaboration: 908 Devices, Dana-Farber, Bruker

Using CE-HPMS for Accelerated Process Development of a mAb-expressing Cell Line
Collaboration: 908 Devices, CPI

RapidCharacterization of Oligonucleotides and Related Impurities using MicrochipCE-MS Without Ion-pairing Reagents
Collaboration: 908 Devices, Thermo Fisher Scientific

Multi-levelExpeditious Characterization of Adeno-associated Virus (AAV) Capsid ProteinsUsing ZipChip Microfluidic CE Coupled with HRMS
Collaboration: 908 Devices, Thermo Fisher Scientific

Bottom-up Analysis of Progressively Larger RNAs by CZE-MS and CZE-MS/MS
Collaboration: 908 Devices, University of Connecticut, Bruker

For more information about our ASMS presentations, visit Mass Spec For the Masses - 908 Devices.

All the above presentations including a recording of the oral presentation are available on demand to current ASMS members and meeting attendees via the 2022 conference portal.


About 908 Devices

908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties, and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.